Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: LLY.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Eli Lilly and (LLY) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

$1,244

+7.9%+8.6% incl. dividends

2031

5-Year

NEUTRAL

$1,630

+41.4%+45.7% incl. dividends

Published batch insight

Metabolic Volume Scaling Converts Surging Demand Into Massive Cash Generation

There is high consensus that surging cardiometabolic prescription volume and oral small-molecule adoption will double operational earnings over five years. However, sharp divergence exists regarding valuation durability, as persistent gross-to-net price erosion and elevated bond yields enforce mechanical multiple compression.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Warren Buffett (Value Purist), J.P. Morgan (Titan), Michael Burry (Vulture), Sherlock Holmes (Whistleblower), Superintelligence (Anthropologist), Universal Investor (Polymath), Ray Dalio (Strategist), Elon Musk (Visionary), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Eli Lilly and at the forecast anchor (2026-09-18): $14,569 in five years versus $13,892 for S&P 500 benchmark.

Eli Lilly and · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 0.6% net dividend yield for Eli Lilly and.

Figure: Five-year synthesized consensus value path for Eli Lilly and compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 1,152.93 USD1-year price return: +7.91%5-year price return: +41.40%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	1,176.95	+2.08%	+2.08%	Robust third-quarter incretin volumes and early oral channel fill drive solid revenue growth, though elevated Treasury yields constrain multiple expansion.
Q1 2027	1,213.97	+3.15%	+5.29%	Record full-year earnings confirm expanding operating cash flow, but conservative guidance highlights ongoing gross-to-net realized price concessions across commercial books.
Q2 2027	1,241.29	+2.25%	+7.66%	Scaling small-molecule oral manufacturing lowers unit costs and expands margins, counterbalancing the implementation of statutory government price demonstration models.
Q3 2027	1,244.13	+0.23%	+7.91%	Mid-year formulary rebate renegotiations induce temporary gross-to-net margin compression, keeping equity price appreciation subdued despite rising patient script counts.
Q4 2027	1,278.22	+2.74%	+10.87%	Pivotal regulatory submissions for triple-agonist retatrutide and expanded cardiometabolic comorbidity indications re-energize forward earnings visibility and institutional accumulation.
Q1 2028	1,310.97	+2.56%	+13.71%	Full-year results highlight surging free cash conversion as prior manufacturing builds achieve operational validation, funding expanded share repurchases.
Q2 2028	1,339.92	+2.21%	+16.22%	Initial commercial launch preparations for retatrutide offset headline noise from competitor trial readouts, preserving steady underlying operating profit growth.
Q3 2028	1,349.41	+0.71%	+17.04%	Election-year drug pricing rhetoric and Medicare negotiation announcements create sector multiple drag, temporarily masking double-digit international volume gains.
Q4 2028	1,390.88	+3.07%	+20.64%	Broadened commercial reimbursement for obesity-related heart failure and sleep apnea drives high-margin volume, supporting a constructive year-end equity advance.
Q1 2029	1,415.22	+1.75%	+22.75%	Annual financial disclosures demonstrate operating income surpassing fifty billion dollars, with oral formulations capturing substantial primary-care and emerging-market share.
Q2 2029	1,439.25	+1.70%	+24.83%	Challenger entries in oral and dual-agonist categories prompt selective commercial discounting, moderating quarterly profit growth to low single digits.
Q3 2029	1,446.75	+0.52%	+25.48%	Manufacturing efficiencies across automated production campuses widen gross margins, absorbing domestic price erosion and generating solid sequential cash earnings.
Q4 2029	1,480.50	+2.33%	+28.41%	Sustained free cash flow generation enables accelerated debt retirement and share repurchases, reinforcing per-share intrinsic value despite broader macro deceleration.
Q1 2030	1,503.02	+1.52%	+30.37%	Publication of statutory Medicare Maximum Fair Price schedules enforces structural price adjustments, curbing multiple expansion while baseline volumes remain resilient.
Q2 2030	1,530.73	+1.84%	+32.77%	International sales expansion across Asia and Latin America compensates for domestic pricing friction, maintaining steady operating cash-flow generation.
Q3 2030	1,536.63	+0.39%	+33.28%	Maturing incretin market penetration shifts institutional focus toward defensive cash harvesting, resulting in modest, earnings-backed quarterly equity appreciation.
Q4 2030	1,570.72	+2.22%	+36.24%	Advancements in next-generation amylin and neurodegenerative pipelines extend the intellectual property runway, supporting terminal valuation multiples into year-end.
Q1 2031	1,589.21	+1.18%	+37.84%	Fiscal 2030 results validate over thirty-five billion dollars in distributable free cash flow, translating business compounding into steady share gains.
Q2 2031	1,608.75	+1.23%	+39.54%	Stable chronic refill demand insulates operations from late-cycle economic headwinds, though early biosimilar preparation headlines restrict multiple re-expansion.
Q3 2031	1,630.20	+1.33%	+41.40%	The five-year forecast culminates with the enterprise operating as a mature global cash generator, cementing durable low-double-digit compounding returns.

The base-case investment thesis resolves around a powerful economic tension: unprecedented volumetric expansion across metabolic franchises versus persistent valuation multiple compression. Surging prescription demand for injectable tirzepatide, combined with the primary-care rollout of oral orforglipron, drives revenue from eighty billion dollars toward one hundred thirty billion dollars. Because multi-billion-dollar manufacturing investments have crest commercial validation, operating margins hold above forty-four percent, converting scale into immense free cash flow. Nonetheless, valuation multiples face systemic compression from thirty-nine times toward twenty-four times earnings under five percent benchmark yields and statutory drug price negotiations. Net earnings expansion comfortably outpaces multiple deflation, securing durable total returns.

Key insights

Oral small-molecule commercialization decouples volume growth from complex injectable cold-chain logistics, unlocking primary-care demographics at structurally superior marginal production costs.
Cresting manufacturing capital expenditures transition the corporate capital structure from cash absorption into prolific free cash flow generation exceeding thirty billion dollars.
Statutory Medicare negotiations and pharmacy benefit manager rebate widening enforce double-digit realized price erosion, establishing volume growth as the sole earnings driver.

Deep Dive

Outside market consensus views the company as an unassailable biopharmaceutical monopoly destined for frictionless thirty-percent annual growth. Investors anchor on boundless global obesity demand, expecting oral therapies to simply stack on top of injectable sales without margin dilution. The prevailing narrative assumes permanent pricing hegemony, blithely discounting sovereign reimbursement pushback and higher interest rates.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd materially overestimates the permanence of peak gross pricing power while underestimating the structural cash conversion of maturing manufacturing assets. External models focus on list prices, ignoring inevitable gross-to-net erosion from statutory Medicare caps and commercial pharmacy benefit manager rebates. However, the market simultaneously overlooks how oral small-molecule synthesis eliminates cold-chain capital intensity, unlocking massive low-cost volume that generates superior free cash conversion.

Repricing catalyst

Transparent net price disclosures in upcoming audited filings, coupled with initial commercial prescription data for oral orforglipron through 2027, will force a market repricing. Investors will directly observe that revenue growth is powered by explosive unit volume rather than pricing power, compelling an orderly valuation multiple compression alongside significant upward revisions in cash generation.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of restrictive monetary policy and ten-year Treasury yields hovering near five percent is a clear valuation headwind for high-multiple equities. However, cardiometabolic disease treatments exhibit virtually zero economic cyclicality; highly inelastic patient demand completely insulates core operating cash flows from broader stagflationary pressures.

Published consensus context

Advisor disagreement

The decisive analytical debate centers on valuation sensitivity and the trajectory of net price realization. Bullish perspectives argue that manufacturing debottlenecking, primary-care oral distribution, and label expansions into sleep apnea and heart failure will drive earnings growth that easily defends premium valuation multiples. Conversely, contrarians demonstrate that statutory Medicare price negotiations and commercial pharmacy benefit manager rebates will compress realized prices by low-to-mid-teens percentages annually. This disagreement will be resolved as quarterly SEC disclosures reveal whether gross margins can hold above eighty-two percent as volume expands.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Incretin franchise volume scaling: Tirzepatide maintains undisputed clinical efficacy, converting diabetes and obesity treatment into chronic maintenance therapy. Expanding manufacturing capacity unlocks global commercial delivery, driving prescription volumes that easily overwhelm low-to-mid-teens gross-to-net realized price concessions and generating massive operational leverage. Expected impact: +30%.
Oral small molecule primary care expansion: Commercial rollout of oral orforglipron bypasses cold-chain logistics and autoinjector shortages, opening primary-care and emerging-market channels. Low chemical synthesis costs elevate gross margins, accelerating cash conversion and dramatically broadening the treated patient pool beyond injectable cohorts. Expected impact: +24%.
Triple agonist clinical differentiation: Pivotal Phase 3 data for retatrutide demonstrating unprecedented weight reduction establishes an insurmountable clinical moat in severe metabolic disease. This clinical superiority protects premium formulary placement and insulates future corporate revenues against early-generation peptide generic erosion. Expected impact: +20%.
Manufacturing scale drives operating leverage: Multi-billion-dollar domestic and international capital deployments are transitioning from cash-absorptive construction into operational production. Yield optimization and fixed-cost dilution reduce unit production costs, expanding operating margins toward forty-six percent and generating prolific free cash flow. Expected impact: +16%.

Top frictions and headwinds

Valuation multiple contraction under rate gravity: Persistent benchmark Treasury yields near five percent and restrictive monetary policy elevate equity discount rates. A trailing price-to-earnings multiple of nearly thirty-nine times faces mechanical compression toward historical pharmaceutical averages of twenty-two to twenty-six times, dampening equity returns. Expected impact: -18%.
Statutory drug price negotiations and discounts: Implementation of Inflation Reduction Act mechanisms and mandatory statutory caps forces significant gross-to-net price concessions across government and commercial programs. This institutional price erosion constrains unit profitability, requiring relentless volume expansion merely to preserve margin health. Expected impact: -16%.
Competitive pipeline crowding and rebate warfare: Rival combination therapies, next-generation oral incretins, and compounded peptide alternatives enter commercial channels. Pharmacy benefit managers leverage competing options to demand steeper formulary rebates, eroding pricing leverage and forcing defensive commercial marketing expenditures. Expected impact: -12%.
Heavy pipeline development and fixed depreciation: Capitalizing newly commissioned manufacturing facilities introduces substantial depreciation charges onto the income statement. Concurrently, recurring multi-billion-dollar acquired research and development outlays compete with shareholder distributions, keeping distributable cash flow below headline net income. Expected impact: -9%.

Tail risks

Severe idiosyncratic class wide safety restriction: Emergence of a verified, severe adverse post-marketing safety signal—such as persistent gastrointestinal dysmotility or oncogenic pathology—could prompt FDA black-box warnings. Such intervention would trigger sudden patient discontinuations, severe product liability litigation, and a catastrophic derating of the core metabolic franchise valuation. Probability: +16%. Expected impact: -34%.
Radical mandatory statutory price parity decrees: Aggressive executive decrees or statutory cost-containment reforms tying domestic metabolic reimbursement directly to international reference prices would dismantle US commercial pricing structures. Slashing net realized prices by fifty percent would destroy operating leverage, gutting free cash generation and wiping out hundreds of billions in market capitalization. Probability: +22%. Expected impact: -28%.

Tail opportunities

Universal statutory obesity coverage mandate: Bipartisan passage of federal legislation or binding CMS rulemaking mandating universal Medicare and commercial coverage for anti-obesity medications would instantly unlock forty million insured lives. This policy breakthrough would overwhelm statutory price discounts, adding over fifteen billion dollars in annual revenue and triggering aggressive multiple expansion. Probability: +34%. Expected impact: +28%.
Definitive neurodegenerative disease modification victory: Landmark Phase 3 readouts demonstrating profound slowing of cognitive decline for donanemab or next-generation tau conjugates would establish a second multi-billion-dollar therapeutic pillar. Validating disease modification beyond incretins would eliminate single-franchise concentration risk, unlocking substantial institutional scarcity premiums and re-rating the firm's terminal valuation. Probability: +23%. Expected impact: +22%.

What to monitor

Thesis watchpoints

-- Quarterly incretin prescription volume growth maintaining above thirty-five percent year-over-year validates dominant mass-market commercial adoption through 2027.

Key insights

Realized net price declines exceeding twelve percent annualized across commercial books signals severe formulary rebate erosion across 2027.
Inclusion of tirzepatide in statutory Medicare Maximum Fair Price negotiations before 2028 requires immediate downward intrinsic valuation adjustments.

Company Financial Analysis

Eli Lilly and Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

The latest financial performance illustrates an extraordinary volume-driven expansion. Trailing twelve-month revenue surged to nearly eighty billion dollars, propelled by explosive prescription demand for diabetes and weight-loss blockbusters that overwhelmed single-digit price discounts. Net income expanded dramatically to over twenty-six billion dollars as fixed corporate overhead was spread across massive unit sales. However, headline accounting figures conceal important cash details. While trailing free cash flow reached a record twenty billion dollars, recurring multi-billion-dollar charges for acquired research partnerships continue to absorb cash. The underlying business is growing exceptionally fast, but investors must recognize that ongoing pipeline acquisitions remain an essential expense to maintain long-term leadership.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 65.2B	USD 20.6B	USD 9B
2024	USD 45B	USD 10.6B	USD 414.3M
2023	USD 34.1B	USD 5.2B	USD -3.2B
2022	USD 28.5B	USD 6.2B	USD 4.6B
2021	USD 28.3B	USD 5.6B	USD 5.4B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	46.8x	TTM	Native	USD / USD
2024	65.8x	TTM	Native	USD / USD
2023	>100x	TTM	Native	USD / USD
2022	55.7x	Annual	Native	USD / USD
2021	47.2x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability has expanded to historic highs, with gross profit margins reaching eighty-three percent and operating margins widening to nearly forty-six percent. This remarkable efficiency reflects immense manufacturing scale and a favorable shift toward high-margin metabolic treatments that cost relatively little to produce once factories are running. These elite margins face an inevitable tug-of-war. Growing government price caps and insurance rebates will push realized selling prices lower, but newly approved daily pills have much cheaper production and shipping costs than refrigerated injections. This structural cost advantage should keep long-term operating profit margins exceptionally strong near forty-four percent.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 29.7B	45.6%	31.7%
2024	USD 17B	37.8%	23.5%
2023	USD 10.8B	31.6%	15.4%
2022	USD 8.7B	30.3%	21.9%
2021	USD 7.9B	28.0%	19.7%

Balance sheet and leverage

AI Review

The company's balance sheet has strengthened dramatically, supported by total assets expanding to one hundred twelve billion dollars and stockholders' equity nearly doubling to over twenty-six billion dollars. Explosive operational earnings have driven interest coverage to an impregnable thirty-seven times, rendering debt obligations exceptionally safe despite high interest rates. headline net debt of roughly forty-six billion dollars reflects aggressive strategic expansion rather than operating distress. Surging annual cash flow easily handles upcoming debt maturities, granting management complete autonomy to fund clinical trials and selective acquisitions without needing to borrow expensive capital or issue dilutive new shares.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 42.5B	USD 7.3B	USD 35.3B net debt	1.58x
2024	USD 33.6B	USD 3.4B	USD 30.4B net debt	1.15x
2023	USD 25.2B	USD 2.9B	USD 22.4B net debt	0.94x
2022	USD 16.2B	USD 2.2B	USD 14.2B net debt	1.05x
2021	USD 16.9B	USD 3.9B	USD 13.1B net debt	1.23x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management has executed a massive, multi-year industrial building campaign, pouring tens of billions of dollars into high-tech manufacturing plants across Indiana, North Carolina, and Europe. Capital expenditure consumed nearly nineteen percent of revenue in 2024 before moderating to twelve percent in 2025 as major facility phases reached completion. This aggressive spending was necessary to eliminate chronic drug shortages and build automated facilities that competitors cannot easily replicate. Because the heaviest construction phase is now cresting, future capital spending will moderate relative to sales. This unlocks billions in surplus cash flow that can be redirected toward shareholder dividends and share buybacks.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 7.8B	USD 13.3B
2024	USD 8.4B	USD 11B
2023	USD 7.4B	USD 9.3B
2022	USD 2.5B	USD 7.2B
2021	USD 1.9B	USD 6.9B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	119	+9.9%	Not available	ORIGINAL
5Y	NEUTRAL	102	+47.1%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	1,083.75	1,183.4	1,210.58	14
+6M	March 18, 2027	1,116.27	1,222.35	1,259	14
+9M	June 18, 2027	1,150.7	1,248.45	1,296.77	14
+1Y	September 18, 2027	1,104.68	1,259.69	1,348.64	14
+15M	December 18, 2027	1,115.72	1,294.98	1,402.07	14
+18M	March 18, 2028	1,160.35	1,320.49	1,458.55	14
+21M	June 18, 2028	1,183.56	1,349.48	1,516.9	14
+2Y	September 18, 2028	1,148.05	1,362.13	1,516.91	14
+27M	December 18, 2028	1,171.01	1,403.17	1,577.59	14
+30M	March 18, 2029	1,147.59	1,431.03	1,624.92	14
+33M	June 18, 2029	1,182.02	1,448.69	1,657.42	14
+3Y	September 18, 2029	1,205.66	1,463.45	1,690.56	14
+39M	December 18, 2029	1,241.83	1,496.62	1,741.28	14
+42M	March 18, 2030	1,229.41	1,519.34	1,776.11	14
+45M	June 18, 2030	1,254	1,547.19	1,793.87	14
+4Y	September 18, 2030	1,266.54	1,552.95	1,829.75	14
+51M	December 18, 2030	1,291.87	1,587.35	1,866.34	14
+54M	March 18, 2031	1,266.03	1,608.54	1,885	14
+57M	June 18, 2031	1,291.36	1,627.89	1,903.85	14
+5Y	September 18, 2031	1,304.27	1,649.84	1,922.89	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The independently supported consensus reveals an extraordinary operational transition: massive volume expansion driven by tirzepatide indications, the commercial scaling of oral small-molecule orforglipron, and late-stage retatrutide clinical data. Most submissions agree that multi-billion-dollar domestic biomanufacturing investments have passed peak capital intensity, unlocking substantial free cash flow conversion. However, reports heavily correlated around unconstrained growth overlook critical gross-to-net price erosion and statutory Medicare drug price negotiations. The strongest contrarian case establishes that realized prices face low-to-mid-teens annual deflation and that persistent five percent benchmark bond yields will grind trailing valuation multiples toward historical sector norms. We assign higher weights to forensic analyses that rigorously reconcile cash-flow statements by isolating acquired research charges from core manufacturing capital expenditures. Unresolved uncertainty centers on whether unit volume elasticity can fully outrun sovereign price caps.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight12.5/100

Provides exemplary empirical rigor, independently reconciling Form 10-K and 10-Q cash flow discrepancies while distinguishing manufacturing capital expenditures from acquired research charges. Its realistic price-for-access trade-off deserves substantial weight.

AI RESEARCHER

Michael Burry AI

The Vulture

The Polymath

Opus 5

Weight1.0/100

Demonstrates strong primary research and patent timeline verification, but its factual baseline relies on post-cutoff future reporting and forward-dated regulatory artifacts, necessitating a minimal weighting for audit compliance.

Skip to references

Research Provenance

References & Context

This Eli Lilly and consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 64 deduplicated sources retained for this batch.

01Medicare GLP-1 Bridge | CMScms.gov
02Documentsec.gov
03ELI LILLY & Co - Form 8-K - FY2026sec.gov
04lly-20251231sec.gov
05lly-20260630sec.gov
06Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress | Eli Lilly and Companyinvestor.lilly.com
07Eli Lilly (LLY) Earnings Report Q2 2026 | Beat, EPS & Revenue | 24/7 Wall St.247wallst.com
08FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity | AJMCajmc.com
09Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices | AJMCajmc.com
10Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s | AMCP.orgamcp.org
11Eli Lilly Q2 2026 results: revenue +48%, raises guidance; retatrutide package completechemxplore.com
12Eli Lilly (LLY) earnings Q2 2026cnbc.com
13When do the MOUNJARO patents expire, and when will generic MOUNJARO be available?drugpatentwatch.com
14FDA Accepts Sandoz Applications for Generic Tirzepatide | Drug Topicsdrugtopics.com
15Lilly builds sizable store of orforglipron ahead of FDA verdictfiercepharma.com

And 49 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.